Tag: ER+/PR-

Articles

• Breast cancer types
• ER+/PR- breast cancer
• Hormone receptor and HER2 status changes can influence prognosis
• How important is Vitamin D before and after breast cancer diagnosis?
• How to optimize your breast cancer diet
• Latest research concerning breast cancer in Asian Americans
• Latest research concerning mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis
• Latest research on hormone replacement therapy and breast cancer
• When should mastectomy be followed by radiation treatment?

News

• 5 years of tamoxifen reduces breast cancer mortality for 15 years for ER+ disease
• A story of long-term stage IV HER2+ breast cancer survival
• Age and breast cancer subtype influence prognosis after lumpectomy
• Although similar, ER+/PR- breast cancer is more aggressive than ER+/PR+
• Asian-American women have higher rates of HER2-positive breast cancer than Caucasians
• Aspirin use is associated with reduced risk of breast cancer, but ibuprofen may increase it
• Aspirin use reduces risk of all hormone receptor types of breast cancer
• Coexisting DCIS independently predicts lower tumor aggressiveness in luminal breast cancer
• Combination HRT doubles breast cancer risk among women with breast tenderness
• DCIS incidence has increased in recent years
• Dense breasts are linked to increased risk of hormone receptor positive and mixed receptor tumors
• Differences in hormone receptor status between primary breast tumor and mets is common
• Different breast cancer subtypes are prone to metastasize to different sites in the body
• Drop in hormone replacement therapy use explains part of decline in breast cancer rates
• ER negative, PR negative, and triple negative tumors have increased risk of locoregional recurrence
• ER+/PR- or ER-/PR+ tumors more likely to recur locally than ER+/PR+ breast cancer
• Five-year prognosis by breast cancer subtype
• High circulating hormones increase risk of breast cancer for postmenopausal women
• High dose vitamin D reduces musculoskeletal symptoms in women taking Arimidex
• Hormone receptor status changes during progression in over one-third of breast cancer cases
• Knowing the receptor status of metastases improves treatment decisions
• Luminal breast cancer prognosis can vary based on other tumor characteristics
• Migraine sufferers have lower risk of ER+/PR+ tumors - implications for choice of treatment
• Patients with ER-/PR+ breast cancer benefit from endocrine therapy
• Serotonin in breast cancer cells contributes to malignant growth
• Small triple negative tumors have worse prognosis than small ER+/PR+ tumors
• Statin use increases risk of breast cancer for overweight women
• Survival times of stage IV breast cancer patients depends on progesterone receptor status
• Vitamin A can both promote and inhibit breast cancer growth and metastasis
• Vitamin D and calcium intakes influence risk of breast cancer
• Women with high BMI may benefit less from hormonal treatments

Studies

• A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences
• A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative
• Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
• Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis
• Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy
• Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women
• Antidepressant use and breast cancer risk
• Apigenin augments the growth inhibitory effects of doxorubicin in breast cancer cells derived from African American patients
• Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study
• Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers
• Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort
• Brain metastases free survival differs between breast cancer subtypes
• Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
• Clinically Used Breast Cancer Markers Are Heterogeneous Throughout Tumour Progression
• Conjugated linoleic acid intake and breast cancer risk in a prospective cohort of Swedish women
• Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health-AARP Diet and Health Study
• Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status - A prospective cohort study among Swedish women
• Dietary lignans and postmenopausal breast cancer risk by oestrogen receptor status: a prospective cohort study of Swedish women
• Discordance in hormone receptor status in breast cancer during tumor progression
• Does progesterone receptor status matter in endocrine-responsive breast cancer?
• Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
• Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
• Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study
• Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
• Effect of dietary fiber intake on breast cancer risk according to estrogen and progesterone receptor status
• Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer
• ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies
• Estrogen receptor positive operable breast cancer: Does menopausal status impact on HER2 and progesterone receptor status?
• Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer
• Folate Intake and Risk of Breast Cancer by Estrogen and Progesterone Receptor Status in a Swedish Cohort
• Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women
• HDL of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells
• Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
• Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women
• Mammographic density and hormone receptor expression in breast cancer: The Multiethnic Cohort Study
• Molecular Alterations Between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor
• Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark
• Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype
• Outcome of special types of luminal breast cancer
• Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer
• Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer
• Polyphenol-rich seaweed (Eucheuma cottonii) extract suppresses breast tumour via hormone modulation and apoptosis induction
• Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
• Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller
• Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
• Relationship of body mass index to the intrinsic subtypes of breast cancer
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
• Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells
• Risk factors for postmenopausal breast cancer defined by estrogen and progesterone receptor status: The multiethnic cohort
• Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation
• Surgery for widely disseminated breast cancer: prolonged control by excision of metastases
• Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010
• The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer
• The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors
• Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
• Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
• Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer